drugset / Trial / NCT00864071

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

NCT00864071

Phase 1 Completed 50 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the rate and extent of absorption of griseofulvin from a test formulation of Griseofulvin 125 mg/5 mL Suspension versus the reference Grifulvin V® 125 mg/5 mL Suspension under fasting conditions.

Timeline

Start
2005-11
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Griseofulvin Small molecule 125 mg

Indications

No indication recorded.